Cargando…

Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic

Introduction Proton pump inhibitors (PPI) are commonly prescribed in the primary care setting. While generally considered to be safe, there is growing evidence suggesting that PPI misuse is associated with a variety of significant adverse outcomes and unnecessary cost. The goal of this quality impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Boster, Joshua, Lowry, Lacy E, Bezzant, Matthew L, Kuiper, Brandon, Surry, Luke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008731/
https://www.ncbi.nlm.nih.gov/pubmed/32064190
http://dx.doi.org/10.7759/cureus.6609
_version_ 1783495523253092352
author Boster, Joshua
Lowry, Lacy E
Bezzant, Matthew L
Kuiper, Brandon
Surry, Luke
author_facet Boster, Joshua
Lowry, Lacy E
Bezzant, Matthew L
Kuiper, Brandon
Surry, Luke
author_sort Boster, Joshua
collection PubMed
description Introduction Proton pump inhibitors (PPI) are commonly prescribed in the primary care setting. While generally considered to be safe, there is growing evidence suggesting that PPI misuse is associated with a variety of significant adverse outcomes and unnecessary cost. The goal of this quality improvement project was to identify patients with non-guideline recommended PPI prescriptions in our internal medicine residency clinics and implement a process to de-prescribe or reduce the dose of PPIs across this patient population. Methods PPI prescription rates, dosage, and indication were extracted from the medical records of all 854 patients empaneled to the internal medicine residency clinics at a multicenter closed referral military hospital system. Appropriate PPI indication was consensus based upon published guidelines, and patients without an appropriate indication were targeted for intervention. These patients were directly contacted by their primary care physicians, via phone or during a clinic visit, to discuss the risks and benefits of ongoing PPI use as well as alternative therapies or tapering regimens at the physician’s discretion. For moderate to high dose PPI, the dose was decreased by 50% every week until the lowest tolerated dose was achieved or until discontinuation. For low dose PPI, discontinuation was recommended as the initial intervention. Six months following the intervention, the empanelment was reevaluated for ongoing PPI usage, tapered dosage, or discontinuation. Results Of a total of 854 patient records reviewed at the initiation of the project, 322 patients were noted to be prescribed PPIs. Of this subset, 66% (217/322) did not meet a guideline recommended indication for their use. At the completion of the six-month intervention period, 44% (96/217) of patients were successfully weaned to a reduced dose or were no longer using a PPI. Conclusions PPIs are widely used and generally considered to be a well-tolerated therapy for acid-secretion disorders. PPI overprescription and the associated adverse effects and economic burden are increasingly recognized. We show that a simple, focused, resident-driven quality improvement intervention can be effective in de-prescribing efforts to reduce inappropriate PPI use in the outpatient primary care setting.
format Online
Article
Text
id pubmed-7008731
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-70087312020-02-15 Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic Boster, Joshua Lowry, Lacy E Bezzant, Matthew L Kuiper, Brandon Surry, Luke Cureus Internal Medicine Introduction Proton pump inhibitors (PPI) are commonly prescribed in the primary care setting. While generally considered to be safe, there is growing evidence suggesting that PPI misuse is associated with a variety of significant adverse outcomes and unnecessary cost. The goal of this quality improvement project was to identify patients with non-guideline recommended PPI prescriptions in our internal medicine residency clinics and implement a process to de-prescribe or reduce the dose of PPIs across this patient population. Methods PPI prescription rates, dosage, and indication were extracted from the medical records of all 854 patients empaneled to the internal medicine residency clinics at a multicenter closed referral military hospital system. Appropriate PPI indication was consensus based upon published guidelines, and patients without an appropriate indication were targeted for intervention. These patients were directly contacted by their primary care physicians, via phone or during a clinic visit, to discuss the risks and benefits of ongoing PPI use as well as alternative therapies or tapering regimens at the physician’s discretion. For moderate to high dose PPI, the dose was decreased by 50% every week until the lowest tolerated dose was achieved or until discontinuation. For low dose PPI, discontinuation was recommended as the initial intervention. Six months following the intervention, the empanelment was reevaluated for ongoing PPI usage, tapered dosage, or discontinuation. Results Of a total of 854 patient records reviewed at the initiation of the project, 322 patients were noted to be prescribed PPIs. Of this subset, 66% (217/322) did not meet a guideline recommended indication for their use. At the completion of the six-month intervention period, 44% (96/217) of patients were successfully weaned to a reduced dose or were no longer using a PPI. Conclusions PPIs are widely used and generally considered to be a well-tolerated therapy for acid-secretion disorders. PPI overprescription and the associated adverse effects and economic burden are increasingly recognized. We show that a simple, focused, resident-driven quality improvement intervention can be effective in de-prescribing efforts to reduce inappropriate PPI use in the outpatient primary care setting. Cureus 2020-01-09 /pmc/articles/PMC7008731/ /pubmed/32064190 http://dx.doi.org/10.7759/cureus.6609 Text en Copyright © 2020, Boster et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Boster, Joshua
Lowry, Lacy E
Bezzant, Matthew L
Kuiper, Brandon
Surry, Luke
Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic
title Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic
title_full Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic
title_fullStr Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic
title_full_unstemmed Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic
title_short Reducing the Inappropriate Use of Proton Pump Inhibitors in an Internal Medicine Residency Clinic
title_sort reducing the inappropriate use of proton pump inhibitors in an internal medicine residency clinic
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008731/
https://www.ncbi.nlm.nih.gov/pubmed/32064190
http://dx.doi.org/10.7759/cureus.6609
work_keys_str_mv AT bosterjoshua reducingtheinappropriateuseofprotonpumpinhibitorsinaninternalmedicineresidencyclinic
AT lowrylacye reducingtheinappropriateuseofprotonpumpinhibitorsinaninternalmedicineresidencyclinic
AT bezzantmatthewl reducingtheinappropriateuseofprotonpumpinhibitorsinaninternalmedicineresidencyclinic
AT kuiperbrandon reducingtheinappropriateuseofprotonpumpinhibitorsinaninternalmedicineresidencyclinic
AT surryluke reducingtheinappropriateuseofprotonpumpinhibitorsinaninternalmedicineresidencyclinic